Published 2 days ago • loading... • Updated 9 hours ago

Trastuzumab Deruxtecan Plus Pertuzumab Improves Progression-Free Survival in Patients With HER2+ Metastatic Breast Cancer

Summary by Pharmacy Times

The meaningful results were reported in the DESTINY-Breast09 trial.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

6 Articles

All

Left

Center

Right

oncnursingnews.com

T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

9 hours ago

Read Full Article

Clinical Trials Arena

Daiichi and AstraZeneca's Enhertu shows PFS benefits in breast cancer trial

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.The post Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial appeared first on Clinical Trials Arena.

2 days ago

Read Full Article

cancernetwork.com

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

2 days ago

Read Full Article

Pharmacy Times

Trastuzumab Deruxtecan Plus Pertuzumab Improves Progression-Free Survival in Patients With HER2+ Metastatic Breast Cancer

The meaningful results were reported in the DESTINY-Breast09 trial.

2 days ago

Read Full Article

targetedonc.com

DESTINY-Breast09: T-DXd Plus Pertuzumab Leads in HER2+ Breast Cancer

The DESTINY-Breast09 trial showed that first-line fam-trastuzumab deruxtecan plus pertuzumab improved progression-free survival in HER2+ metastatic breast cancer.

2 days ago

Read Full Article

curetoday.com